EULAR updated its recommendations for the management of Behçet's syndrome in 2025.[1][2] Behçet's syndrome is a systemic vasculitis with heterogeneous manifestations.[1] It requires individualized treatment strategies to preserve organ function and quality of life.[1] It is not possible to develop one standard treatment strategy.[1] These guidelines assist physicians in the management of this challenging disease in rheumatology.[1] The update is based on new evidence and improves patient care.[1][2]